Publication Beamlines Strategic Pillar
Cregg, James; Edwards, Anne V.; Chang, Stephanie; Lee, Bianca J.; Knox, John E. et al. (2025). Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers. Journal of Medicinal Chemistry . 10.1021/acs.jmedchem.4c02314. CMCF-ID Health
Cregg, James; Pota, Kristof; Tomlinson, Aidan C. A.; Yano, Jason; Marquez, Abby et al. (2025). Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers. Journal of Medicinal Chemistry . 10.1021/acs.jmedchem.4c02313. CMCF-ID Health